MTOR and breast cancer: In 2015, Triolimus, a polymeric micelle formulation developed by Co‐D Therapeutics comprised of PEG–PLA micelles (MN of PEG = 4200 and MN of PLA = 1900) of ca 40 nm encapsulating a combination of PTX, the mTOR inhibitor rapamycin, and the Hsp90 inhibitor tanespimycin (17‐AAG) which exert synergistic activity (Shin et al., 2011), was granted orphan drug designation for the treatment of angiosarcoma (https://co-drx.com/pipeline) and is currently in late‐stage preclinical evaluation for the treatment of breast cancer (BC), NSCLC, and angiosarcoma.